Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
Paolo PozzilliPaul NorwoodEsteban JódarMelanie Jane DaviesTibor IvanyiHonghua JiangD Bradley WoodwardZvonko MilicevicPublished in: Diabetes, obesity & metabolism (2017)
Weekly dulaglutide 1.5 mg added to basal insulin is an efficacious and well tolerated treatment option for patients with T2D.